Skip to content


Cindy Yee brings over 25 years of drug discovery & development, partnership and portfolio experience.  She leads preclinical development, portfolio, project & alliance management.  She joined Good Therapeutics in 2021 and transitioned to Bonum Therapeutics after the acquisition by Roche in 2022.   Previously, she served as Director of Alliances at BeiGene where she led implementation of global strategic partnerships spanning equity investment, clinical collaboration, and licensing arrangements for immuno-oncology therapeutics, and contributed to the build out of the strategy and partnerships organization.  Prior, Cindy was at Alphabet’s life science company Verily as Partnership Engagement and Program Management Lead bringing academic, nonprofit, and global pharma partners together with internal innovative product development teams to create and launch cutting-edge life science technologies in Digital Biomarkers, Neurology, and Baseline’s rapid COVID-19 response.  In her role in Portfolio Program Management at AbbVie she co-led the advancement of internal and partnership immuno-oncology biologics from late research through clinical proof of concept.  Earlier in her career, Cindy held positions of increasing responsibility advancing biologics and small molecules at Merck/Schering-Plough, Genentech, Genencor Intl, and Pharmacia/Searle.